<?xml version="1.0" encoding="UTF-8"?>
<p>As medication experts, pharmacists are in an ideal position to provide information about both conventional treatments and biological-based complementary medicine therapies [
 <xref rid="B63-pharmaceuticals-13-00455" ref-type="bibr">63</xref>]. There is a growing demand for oncology HCPs, including pharmacists, to be able to provide advice that ensures that these products are being used appropriately and safely [
 <xref rid="B58-pharmaceuticals-13-00455" ref-type="bibr">58</xref>,
 <xref rid="B64-pharmaceuticals-13-00455" ref-type="bibr">64</xref>]. However, it has been suggested that a lack of knowledge and education about the efficacy and safety of biological-based products act as a barrier to open discussions between HCPs and their patients [
 <xref rid="B65-pharmaceuticals-13-00455" ref-type="bibr">65</xref>]. In a survey of 70 Australian pharmacists examining perceptions, opinions, and knowledge about the use of complementary medicine by people living with cancer, it was estimated that 19% of daily inquiries were related to the use of biological-based complementary medicine. Furthermore, 72% of respondents believed they had a responsibility to advise about the concomitant use of these products with standard cancer treatments, despite 60% reporting a lack of confidence in their knowledge. The main barriers which were identified as preventing pharmacists from providing information about the use of these products included inadequate training on this subject (94%) and reservations about the evidence base for their efficacy and safety (50%) [
 <xref rid="B63-pharmaceuticals-13-00455" ref-type="bibr">63</xref>].
</p>
